Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, Praxis Precision Medicines Inc.
Deutsche Bank raised the firm’s price target on Praxis Precision (PRAX) to $303 from $270 and keeps a Buy rating on the shares. The company announced a “double whammy of positive news,” the analyst ...
Oppenheimer raised the firm’s price target on Praxis Precision (PRAX) to $250 from $115 and keeps an Outperform rating on the shares. The firm says the company surprised investors with a “double-win” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback